

1. Record Nr.	UNINA9910821000603321
Titolo	Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer // edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz
Pubbl/distr/stampa	Hoboken, New Jersey : , : John Wiley & Sons, Incorporated, , [2017] ©2017
ISBN	1-119-06084-2 1-119-06080-X 1-119-06072-9
Descrizione fisica	1 online resource (566 pages) : color illustrations
Disciplina	615.7/98
Soggetti	Antibody-toxin conjugates Monoclonal antibodies Antineoplastic agents Tumors - Treatment
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC

nonclinical safety assessments / Stacey Ricci and Natalie Simpson --  
Antibody drug conjugates : clinical strategies and applications /  
Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta --  
Antibody-drug conjugates (ADCs) in clinical development / Patricia  
LoRusso and Joseph McLaughlin -- ADCs approved for use :  
Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously  
treated HER2-positive metastatic breast cancer / Gail Lewis Phillips,  
Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved  
for use : Brentuximab Vedotin / Sven DeVos and Monica Mead --  
Radioimmunotherapy / Jeffrey Wong and Savita Dandapani --  
Radiolabeled antibody-based imaging in clinical oncology / Bart  
Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next  
evolution in the cure for cancer -- William C. Olson and Amy Q. Han.

---